FOXA transcription factors are potent, context‐specific mediators of development that hold specialized functions in hormone‐dependent tissues. Over the last several years, FOXA1 has emerged as a critical mediator of nuclear steroid receptor signalling, manifest at least in part through regulation of androgen receptor and oestrogen receptor activity. Recent findings point towards a major role for FOXA1 in modulating nuclear steroid receptor activity in breast and prostate cancer, and suggest that FOXA1 may significantly contribute to pro‐tumourigenic phenotypes. The present review article will focus on the mechanisms, consequence, and clinical relevance of FOXA1‐mediated steroid nuclear receptor signalling in human malignancy.